Sistemic hires more staff
Moves to larger premises that will become new global hq
The company says this will enable it to fulfil current contracts more rapidly, while providing further capacity for newly acquired and future contracts. It will also support the expansion of its key internal r&d programmes in drug toxicology and stem cell characterisation.
The expansion programme will also see the company grow its US commercial operations by developing its Boston location and opening an office in California.
David Mallinson, who previously worked for Merck Sharpe Dohme (MSD), has joined Sistemic as a senior scientist and will lead new projects at the expanded facility.
Max Bylesjo, previously at Almac Group, has joined as senior bioinformatician and will focus on developing Sistemic’s data processing technology.
The new Sistemic headquarters will dedicate 60% of its space to laboratory facilities, equipped with state-of-the-art technology, and 40% as new commercial areas.
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development
AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment
AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy